Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Janux Therapeutics Inc ( (JANX) ).
On January 22, 2026, Janux Therapeutics announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to co-develop a novel, tumor-activated therapeutic targeting a validated solid tumor antigen expressed across multiple human cancer types. Under the deal, Janux will lead preclinical development through IND submission while Bristol Myers Squibb will hold the IND and take responsibility for subsequent clinical development and global commercialization, with Janux supporting through the completion of the first Phase 1 trial. The agreement underscores external validation of Janux’s tumor-activated platforms and could significantly bolster its financial position and long-term revenue prospects, with up to $50 million in upfront and near-term milestone payments, a potential further $800 million in development, regulatory and commercial milestones, and tiered royalties on global product sales, strengthening its strategic positioning in solid tumor oncology and providing potential upside for investors and other stakeholders.
The most recent analyst rating on (JANX) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Janux Therapeutics Inc stock, see the JANX Stock Forecast page.
Spark’s Take on JANX Stock
According to Spark, TipRanks’ AI Analyst, JANX is a Neutral.
Overall score is driven primarily by weak financial performance (widening losses and increasing cash burn) despite a comparatively strong balance sheet. Technicals add pressure due to a clear downtrend, while valuation provides limited support because losses persist and there is no dividend yield.
To see Spark’s full report on JANX stock, click here.
More about Janux Therapeutics Inc
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. Its pipeline includes two TRACTr candidates in Phase 1 trials: JANX007, targeting PSMA for metastatic castration-resistant prostate cancer, and JANX008, targeting EGFR for a range of solid tumors including colorectal, head and neck, lung, renal, pancreatic, and triple-negative breast cancers. The company is also advancing additional CD3-based TRACTr, CD28-based TRACIr, and ARM programs, including a TROP2-TRACTr for TROP2-positive solid tumors and a CD19-ARM for potential treatment of autoimmune diseases.
Average Trading Volume: 2,002,940
Technical Sentiment Signal: Sell
Current Market Cap: $790.9M
Find detailed analytics on JANX stock on TipRanks’ Stock Analysis page.